8-K: Immunic's Vidofludimus Calcium Shows Promise in Progressive Multiple Sclerosis Trial

Immunic's phase 2 CALLIPER trial indicates that vidofludimus calcium reduces the risk of disability worsening in patients with primary progressive multiple sclerosis.

Summary

• Immunic announced positive data from its phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS).
• The trial enrolled 467 patients and evaluated the efficacy, safety, and tolerability of vidofludimus calcium.
• In the overall PMS patient population, vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events by 20% compared to placebo.
• In the primary progressive multiple sclerosis (PPMS) subgroup, a 30% reduction in the relative risk of 24wCDW events was observed compared to placebo.
• A 15% reduction was observed in the non-active secondary progressive multiple sclerosis (naSPMS) subgroup.
• Vidofludimus calcium reduced the annualized rate of thalamic brain volume loss by 20% compared to placebo.
• The drug showed a favorable safety and tolerability profile, with no new safety signals identified.
• The company plans to discuss the results with healthcare authorities to determine the next steps for vidofludimus calcium in PMS.
• Immunic's phase 3 clinical trial program of vidofludimus calcium in relapsing multiple sclerosis is ongoing and expected to be completed in 2026.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for a new treatment option for progressive multiple sclerosis. The safety profile is favorable, and management expresses optimism. However, it's still a phase 2 trial, so further validation is needed.

Positives

• Vidofludimus calcium showed a statistically significant reduction in disability worsening in PMS patients.
• The drug demonstrated a strong effect in the PPMS subgroup, which has a high unmet medical need.
• The safety and tolerability profile of vidofludimus calcium was confirmed.
• The reduction in thalamic brain volume loss suggests a neuroprotective effect.
• The drug showed a benefit in patients without inflammatory lesions at baseline, a group that typically does not respond well to existing therapies.

Negatives

• The benefit on the exploratory primary MRI endpoint (annualized rate of percent brain volume change) was modest (5% improvement compared to placebo).

Risks

• The results are from a phase 2 trial, and further confirmation is needed in phase 3 trials.
• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical trial results, regulatory approvals, and competition.
• The ongoing conflict in Ukraine and the Middle East could impact planned and ongoing clinical trials.
• Increasing inflation, tariffs and macroeconomics trends could impact the business.

Future Outlook

Immunic plans to discuss the phase 2 CALLIPER trial results with healthcare authorities to determine the appropriate next steps for vidofludimus calcium in PMS and the company's phase 3 clinical trial program of vidofludimus calcium in relapsing multiple sclerosis is ongoing and expected to be completed in 2026.

Management Comments

• Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, stated that the results confirm the objectives of the exploratory phase 2 trial and that the company is particularly thrilled to see such a clinically meaningful effect in the PPMS population.
• Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic, added that vidofludimus calcium could become the first real neuroprotective treatment option for patients with progressive forms of MS.

Industry Context

The announcement addresses the significant unmet need for safe and effective therapies to slow or halt disease progression in progressive multiple sclerosis, particularly in PPMS and non-active SPMS, where treatment options are limited.

Comparison to Industry Standards

• The 30% reduction in the relative risk of 24wCDW events in the PPMS population is described as outperforming historic trials in PPMS regarding numerical reduction of disability progression events.
• The press release mentions that only one therapy is currently approved for PPMS, highlighting the unmet need that vidofludimus calcium could potentially address.

Stakeholder Impact

• Positive results could benefit patients with progressive multiple sclerosis by providing a new treatment option.
• Successful development and commercialization of vidofludimus calcium could increase shareholder value.
• The company's employees may benefit from the company's success.

Next Steps

• Immunic will discuss the results with healthcare authorities to determine appropriate next steps for vidofludimus calcium in PMS.
• Analysis of the full CALLIPER data set is ongoing and will be presented at upcoming scientific meetings.
• The company's phase 3 clinical trial program of vidofludimus calcium in relapsing multiple sclerosis is ongoing and expected to be completed in 2026.

Key Dates

Keywords

vidofludimus calcium, IMU-838, multiple sclerosis, progressive multiple sclerosis, PPMS, naSPMS, Nurr1 activator, clinical trial, disability worsening, thalamic brain volume, Immunic